

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Mar-00	TA1	Wisdom teeth removal	impacted wisdom teeth should not be operated on		
Apr-00	TA2	Primary total hip replacement	superseeded by MDA/2012/036		
May-00	TA3	Ovarian cancer- taxanes	Replaced by TA 55	Replaced by TA 55	
May-00	TA4	IHD coronary stents	Replaced by TA 71	Replaced by TA 71	
Jun-00	TA5	Cervical cancer- liquid baed cytology	Replaced by TA69	Replaced by TA 69	
Jun-00	TA6	Breast cancer - taxanes replaced by TA 30	Replaced By TA 30	Replaced by TA 30	
Jul-00	TA7	Dyspepsia - PPIs replaced by CG 17	Replaced by CG 17		
Jul-08	TA8	Hearing aids- withdrawn	withdrawn		
Jul-00	TA9	Diabetes type 2 - rosiglitazone	Replaced by TA 63		No- drug withdrawn
Aug-00	TA10	Inhaler systems ( devices) in children under the age of 5 years with chronic asthma.	For children under the age of 5 years who have chronic stable asthma: Both corticosteroids and bronchodilator therapy should routinely delivered by Pressurised Metered Dose Inhaler (pMDI) and spacer system with a facemask where necessary. Where this combination is not clinically effective for the child, and depending on the child's condition, nebulised therapy may be considered and in the case of children aged 3 to 5 years, a drug powder inhaler (DPI) may also be considered. The choice of which pMDI device and a spacer to use should be determined by the specific needs of the child and how well it works for them. Once these factors have been taken into account the choice should be made on the basis of reducing costs.		
Sep-00	TA 11	Arrythmias ICD- replaced by TA 95	Replaced by TA 95		
Sep-00	TA12	ACS- GP iiB/ iiiAa inhibitors	Replaced by TA 47		
Oct-00	TA13	ADHD methylphenidate	Replaced by TA98		
Oct-00	TA14	Hepatitis C interferon and ribavirin	Replaced by TA 75		
Nov-00	TA15	Flu- zanamivir	Replaced by TA58		
Dec-00	TA16	Knee joints- cartilage transplantation	Replaced by TA 89		
Dec-00	TA17	Colorectal cancer - laparoscopic surgery	This guidance has been replaced by TA105 Colorectal cancer - laparoscopic surgery (review)		
Jan-01	TA18	Hernia (inguinal) - laparoscopic surgery	Replaced by TA83		
Jan-01	TA19	Alzheimer's Disease - donepezil, rivastigmine and galantamine	Replaced by TA111		
Jan-01	TA20	Motor neurone disease	Riluzole should be available for the treatment of individuals with MND in accordance with its licensed indications.	Riluzole	Yes
Mar-01	TA 21	Diabetes type 2 - pioglitazone	Replaced by TA63	Replaced by TA 63	
Mar-01	TA 22	Obesity- orlistat	Replaced by CG 43		
Apr-01	TA23	Brain Cancer - Temozolomide	People with recurrent brain cancer who's initial chemotherapy treatment has failed may be considered for treatment with temozolomide when they have a tumour that it has been shown is malignant through microscopic examination of the tumour cells ( at first relapse). Temozolomide is only recommended as the initial chemotherapy treatment for patients with brain cancer when they are taking part in a clinical trial.	Temozolomide	Yes
Apr-01	TA 24	Wound care - debriding agents	This guidance has been replaced by CG74 surgical site infection.		
May-01	TA25	Pancreatic cancer - gemcitabine	People with advanced or metastatic pancreatic cancer may be treated with gemcitabine as a first line treatment if they have a Karnofsky performance score of 50 or more. Gemcitabine should not be used for people with pancreatic cancer who are suitable for surgery that may cure their cancer, or those who have a Karnofsky performance score of less than 50. gemcitabine should not be used as a second line treatment for people with pancreatic cancer.	gemcitabine	Yes
Jun-01	TA 26	Lung Cancer - docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer.	This guidance has been replaced by CG24	guidance replaced by CG 24	
Jul-01	TA27	Osteoarthritis and rheumatoid arthritis - cox II inhibitors	Replaced by CG59		
Jul-01	TA28	Ovarian cancer - topotecan	Replaced by TA91		
Sep-01	TA29	Leukaemia (lymphocytic) - fludarabine	NICE has recommended that people with B-cell chronic leukaemia (CLL) who have had to stop their first chemotherapy treatment, for example because it was causing side effects or because their disease had progressed may be treated with fludarabine tablets. Fludarabine may be introduced at the stage where people with CLL have previously been offered one of the following treatments; cyclophosphamide, doxorubicin and prednisolone (CHOP), cyclophosphamide doxorubicin and prednisolone (CAP), or cyclophosphamide, vincristine and prednisolone (CVP). People with CLL should only be given fludarabine by drip when their condition is such that they are unable to take tablets.	Fludarabine, cyclophosphamide, doxorubicin and prednisolone,	Yes
Sep-01	TA 30	Taxanes for the treatment of breast cancer	This guidance has been replaced by CG81 Breast Cancer (advanced).	Taxanes	
Oct-01	TA31	Obesity - sibutramine	Replaced by CG43		

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Jan-02	TA32	Multiple Sclerosis - beta interferon and glatiramer acetate	Nice has issued the following advice: A recommendation to use these medicines cannot, presently, be justified, taking both benefits and cost into account. People who are currently taking beta interferon or glatiramer acetate to treat MS could suffer loss of well being if their treatment was stopped when they did not expect it. Because of this, all NHS patient who are on therapy at the date of publication of this guidance should have the option to continue treatment until they and the criteria established for withdrawal from treatment in the Guidelines of the Association of British Neurologists published in January 2001. This advice about continuing treatment also applies to all participating patients at the end of a clinical trial (regardless of whether they were receiving placebo or active drug) and to women whose therapy has been interrupted by pregnancy. The DoH and the National Assembly for Wales, along with the manufacturers of the beta interferon products and glatiramer acetate, have been asked to consider what action could be taken so that the NHS could obtain these drugs in a way that would be cost effective.	beta interferon \ glatiramer acetate	Yes
01/03/2002	TA 33	Colorectal cancer- irinotecan, raltitrexed and oxaliplatin	Replaced by TA 93		
Mar-02	TA34	Breast Cancer - Trastuzumab	Trastuzumab (Herceptin) is recommended for use in combination with paclitaxel for women with tumours with excessive human epidermal growth factor receptor 2 (HER2) at levels of 3+ who have not had chemotherapy for metastatic breast cancer and for whom anthracycline treatment is inappropriate. Trastuzumab by itself is recommended for women with tumours with excessive HER2 at levels of 3+ who have had at least two chemotherapy treatments for metastatic breast cancer. Previous chemotherapy must have included at least an anthracycline drugs and a taxane drug where these treatments are appropriate. It should also have included hormonal therapy in patients sensitive to oestrogen. The level of HER2 protein in the body should be assessed by a clinician using appropriate standards and methods.	Trastuzumab	Yes
Mar-02	TA35	Arthritis (Juvenile idiopathic) - etanercept	Etanercept is recommended for children aged 4 to 17 years who have active JIA in at least five joints and whose condition has not responded adequately to methotrexate or who have been unable to tolerate treatment with methotrexate.	Etanercept	Condition not treated at RFL
Mar-02	TA 36	Rheumatoid arthritis - etanercept and infliximab	This guidance has been replaced by TA130 Rheumatoid arthritis - adalimumab, etanercept and infliximab and TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor	Replaced by TA 135 and 195	
Mar-02	TA 37	Lymphoma - rituximab replaced by TA 137		Replaced by TA 137	
Mar-02	TA38	Asthma older children inhaler devices.	A press-and-breathe pressurised metered dose inhaler used with an appropriate spacer is recommended as the first choice of inhaler for use with inhaled corticosteroid medicines for asthma (preventers). If a clinician believes that it is so unlikely that an individual child will use the press-and-breathe inhaler and spacer properly that his or her asthma control may be affected, other inhalers should be considered. For other inhaler medicines for asthma, such as bronchodilators (relievers), a wider range of inhalers should be considered.	Range of inhaler devices available	
Mar-02	TA39	Smoking cessation - bupropion and nicotine replacement therapy	Replaced by PH10		
Apr-02	TA40	Crohn's disease - Infliximab	This guidance has been replaced by TA187 Crohn's disease - infliximab (review) and adalimumab ( review of TA40)	Replaced by TA 187	
May-02	TA41	Pregnancy - routine Anti-D prophylaxis for RhD negative women	Replaced by TA156		
May-02	TA 42	Human growth hormone for the treatment growth failure in children	This guidance has been replaced by TA188 Human growth hormone (somatropin) for the treatment of growth failure in children (review)	Replaced by TA 188	
Jun-02	TA43	The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for Schizophrenia	This guidance has been replaced by CG82 Schizophrenia (update)	Replaced by CG 82	
Jun-02	TA 44	Hip disease - metal on metal hip resurfacing	In June 2012 the advice about the follow-up of people with metal on metal hip replacements changed (see medical device alert MDA/2012/036 from the MHRA.		
Jul-02	TA45	Ovarian Cancer (Advanced - peg-liposomal doxorubicin)	Replaced by TA91		
Jul-02	TA46	Obesity (morbid) - surgery	Replaced by CG43		
Sep-02	TA 47	Glycoprotein lib/IIa inhibitors in the treatment of acute coronary syndromes	This guidance has been partially updated by 'Unstable angina and NSTEMI (NICE clinical guideline 94).	Partially replaced	Yes
Sep-02	TA48	Renal failure - home versus hospital haemodialysis for patients with end-stage renal failure	The recommendations NICE has made concern only where haemodialysis is carried out ( that is, in the home or in a renal unit). They do not deal with other issues concerning haemodialysis, such as how often it should be carried out, or how it compares with other ways of treating kidney failure.		
Sep-02	TA49	Central venous catheters - ultrasound locating devices	2-D imaging ultrasound guidance should be the preferred method when inserting of central venous catheter into the internal jugular vein in adults and children in elective situations.		
Oct-02	TA50	Leukaemia (chronic myeloid) - imatinib	Replaced by TA70		

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Oct-02	TA51	Depression and anxiety - computerised cognitive behavioural therapy (CCBT)	Replaced by TA97		
Oct-02	TA52	Myocardial Infarction - thrombolysis	This guidance from NICE make recommendations about which thrombolytic drugs should be used for patients who have had a heart attack.	alteplase, reteplase, streptokinase or teneceplase	Yes - teneceplase
Dec-02	TA 53	Diabetes (types 1 and 2) - long acting insulin analogues	NICE has recommended insulin glargine as an option for people with type 1 diabetes. For people with type 2 diabetes who need to take insulin, NICE has recommended that insulin glargine should be an option only if the person; needs help with his or her insulin injections from a carer or healthcare professional, or has repeated an unpleasant hypoglycaemic episodes that significantly affect his or her way of life, or would otherwise need to have two insulin injections to maintain background levels every day as well as having to take other diabetes medicines orally.	Insulin glargine	Yes
Dec-02	TA54	Guidance on the use of vinorelbine for the treatment of advanced breast cancer	This guidance has been replaced by CG81 Breast Cancer (advanced)	vinorelbine- guidance replaced	
Jan-03	TA55	Ovarian Cancer - Paclitaxel	This guidance has been partially updated by 'Paclitaxel, pegylate liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (review) (NICE technology appraisal guidance 91). Recommendations 1.3, 1.4 and 1.5 of TA55 on re-challenge therapy and the second-line treatment of advanced ovarian cancer have been replaced. The recommendations for first-line treatment still stand.	Paclitaxel, peglated liposomal doxorubicin hydrochloride and topotecan	Condition not treated at RFL
Feb-03	TA 56	Stress incontine - vaginal tape	Replaced by CG 40		
Feb-03	TA 57	Insulin pump therapy	Replaced by TA 151		
Feb-03	TA 58	Flu-zanamivir	Replaced by TA168		
Apr-03	TA 59	Electroconvulsive therapy (ECT)	NICE has looked carefully at the evidence and has recommended that ECT should only be used for the treatment of severe depressive illness, a prolonged or severe episode of mania, or catatonia as outlined in the full NICE TA		
Apr-03	TA 60	Diabetes (types 1 and 2) patient education notes	In December 2005 following consultation, the institute proposed that the guidance be updated as part of the reviews of the guidelines on type 1 and type 2 diabetes. The recommendations in this technology appraisal relating to type 2 diabetes have been replaced by recommendations in the Diabetes type 2 (update) clinical guideline published in May 2008. The recommendations in this technology appraisal relating to type 1 diabetes have not changed.		
May-03	TA61	Colorectal cancer - capecitabine and tegafur uracil for metastatic colorectal cancer	NICE has recommended that capecitabine or tegafur with uracil ( and folinic acid), should be among the first options considered for a person with metastatic colorectal cancer. NICE also noted that the use fo capecitabine and tegafur with uracil should be overseen by doctors specialising in the use of medicines for colorectal cancer. In April 2006, following consultation, the Institute decided to make this guidance 'static'. This means that the guidance remains in force and has no scheduled review date.	Capecitabine, tegafur uracil	Yes
May-03	TA 62	Breast Cancer - capecitabine	Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer, this guidance has been replaced by CG81 Breast cancer (advanced).	capecitabine- guidance replaced	
Aug-03	TA63	Diabetes (type 2) - glitazones	Replaced by CG66		
Aug-03	TA64	Growth hormone deficiency (adults) - human growth hormone	Recombinant human growth hormone should be used only for adults with severe growth hormone deficiency that is severely affecting their quality of life.	Recombinant human growth hormone.	Yes
Sep-03	TA65	Non-Hodgkins Lymphoma - Rituximab		Rituximab	Yes
Sep-03	TA66	Bipolar disorder - new drugs	Replaced by CG38		
Sep-03	TA67	Flu prevention - amantidine and oseltamivir	Replaced by TA158		
Sep-03	TA68	Macular degeneration (age-related) photodynamic therapy			
Oct-03	TA69	Cervical Cancer - Cervical screening (review)	NICE has recommended that liquid-based cytology should be used as the main way of preparing samples of cervical cells for cervical screening. NICE has not recommended one product for liquid-based cytology over another as it says that there is currently not enough information about the advantages and disadvantages of the different products.		
Oct-03	TA70	Leukaemia ( chronic myeloid) - imatinib	This guidance has been partially updated by TA241 Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) and TA251 Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib, and standard-dose imatinib.	dasatinib, nilotinib, imatinib inatinib.	, dasatinib NO
Oct-03	TA71	Ischaemic Heart Disease - coronary artery Stents	NICE recommends that stents contain either a drug called sirolimus or one called paclitax. NICE has not made any recommendations on using stents to treat people who have had a heart attack in the previous 24 hours, or people who had a clot in the narrowed artery.	sirolimus and paclitaxel drug eluting stents	Yes
Nov-03	TA 72	RA - ANAKINRA	Replaced by CG 79	Anakinra	No

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Nov-03	TA73	Angina and myocardial infarction - myocardial perfusion scintigraphy	This guidance has been partially updated by 'chest pain of recent onset' (NICE clinical guideline 95) and ' Management of stable angina' (NICE clinical guideline 126). See the quick reference guide and the web format for more information on the updated recommendations.	Not a drug	Not a drug
Jan-04	TA74	Trauma - fluid replacement therapy	NICE has made the following recommendations about giving IV fluid replacement to injured people before they reach hospital. The guidance applies to adults and older children, but does not apply when the only injury is a head injury with no visible bleeding.	Not a drug	Not a drug
Jan-04	TA75	Hepatitis C - pegylated interferons, ribavirin and alfa interferon	This guidance replaces Hepatitis C - alpha interferon and ribavirin (TA14). This guidance is extended by Hepatitis C - peginterferon alfa and ribavirin (TA106).	Peginterferon alfa and Ribavirin	yes
Mar-04	TA76	Epilepsy (adults) - newer drugs	This guidance has been replaced by CG137 Epilepsy	Sodium Valproate and Carbamazepine, Lamotrigine, oxcarbazepine and Topiramate Gabapentin, Levetiracetam, Tiagabine and Vigabatrin,	Yes
Apr-04	TA77	Insomnia - newer hypnotic drugs	NICE has made recommendations about the use of zaleplon, zolpidem and zopiclone to treat insomnia.	Zaleplon, Zolpidem and Zopiclone	Yes zopiclone
Apr-04	TA78	Menstrual bleeding - fluid-filled thermal balloon and microwave endometrial ablation	NICE has recommended that fluid-filled thermal balloon endometrial ablation and microwave endometrial ablation should be options for a woman with heavy menstrual bleeding where surgery is an appropriate way to manage her bleeding.	Not a drug	
Apr-04	TA79	Epilepsy (children) - newer drugs	NICE has made the following recommendations about the use of newer drugs to treat children with epilepsy. If the older drugs do not stop the child from having seizures, one of the newer drugs can be tried, as long as it is suitable for the type of epilepsy the child has, and for the child's age. Specific caution is advised in the use of sodium valproate because of the risk of harm to the unborn child.	Lamotrigine, oxcarbazepine and topiramate. Gabapentin, tiagabine and vigabatrin	Yes
Jul-04	TA80	Acute coronary syndromes - clopidogrel	Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome. Recommendations 1.1 and 1.2 of this guidance have been updated by recommendations 1.3.4 to 1.3.8 in Unstable angina and NSTEMI: the early management of unstable angina and non-ST-segment-elevation myocardial infarction (NICE clinical guideline 94).	clopidogrel	Yes
Aug-04	TA81	Atopic dermatitis (Eczema) topical steroids	NICE has made the following recommendations about the use of topical corticosteroids to treat atopic eczema within the NHS in England and Wales. The recommendations do not apply to topical steroid preparations that also contain other medicines, such as antibiotics.  NICE has recommended that corticosteroids should not be applied to the affected skin of people with atopic eczema more than twice a day.  NICE has recommended that if there is more than one type of topical corticosteroid that would be appropriate for a person's eczema, then the cheapest one should be used.	Topical corticosteroids	Yes
Aug-04	TA82	Atopic dermatitis (Eczema ) pimecrolimus and tacrolimus	Tacrolimus and pimecrolimus should not be used to treat mild atopic eczema. When atopic eczema is moderate or severe, tacrolimus and pimecrolimus should not be used as 'first-line' treatments - that is, they should not be used before other treatments have been tried. But they may be considered in the circumstances below. Tacrolimus may be considered to treat moderate or severe atopic eczema for adults, or children aged 2 years or older, if the maximum strength and potency of topical corticosteroid that is appropriate for the patient's age and the area being treated has been adequately tried and hasn't worked, where there is serious risk of important side effects from further use of topical corticosteroids (particularly permanent damage to the skin). Pimecrolimus may be considered to treat moderate atopic eczema on the face and neck for children aged between 2 and 16 years if the maximum strength and potency of topical corticosteroid that is appropriate for the patient's age and the area being treated has been adequately tried and hasn't worked, where there is serious risk of important side effects from further use of topical corticosteroids ( particularly permanent damage to the skin).	Tacrolimus and pimecrolimus	Yes
Sep-04	TA83	Hernia - laparoscopic surgery (review)	Laparoscopic surgery can be used as an option for repairing inguinal hernia. As with all surgery, there are some risks involved, which may include serious problems just after the operation, pain or numbness in the area of the operation, and the hernia coming back. This guidance replaces TA18 Hernia (inguinal) - laparoscopic surgery.		
Sep-04	TA84	Sepsis (severe) - drotrecogin	Withdrawn		No - drug withdrawn

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Sep-04	TA85	Renal transplantation - immuno-suppressive regimens (adults)	Doctors should consider using basiliximab or daclizumab for induction treatment (immediately after the kidney transplant). These drugs should be used with a combination of other drugs including a calcineurin inhibitor such as ciclosporin. The cheapest one of the two (basiliximab or daclizumab) should be used.	basiliximab, daclizumab, ciclosporin, Tacrolimus, mycophenolate mofetil , Sirolimus.	Yes
Oct-04	TA86	Gastrointestinal stromal tumours - imatinib	This guidance has been partially updated by TA209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib.	imatinib	Condition not treated at RFL
Jan-05	TA87	Osteoporosis - secondary prevention	Replaced by TA161		
Feb-05	TA88	Bradycardia - dual chamber pacemakers	Dual-chamber pacemakers are recommended to treat symptomatic bradycardia in people with sick sinus syndrome, atrioventricular block, or both. But there are a number of special circumstances where dual-chamber pacemakers should not be used for symptomatic bradycardia.		
May-05	TA89	Cartilage injury - autologous chondrocyte implantation (ACI) (review)	ACI is not recommended for treating knee problems caused by damaged articular cartilage, unless it is used in studies that are designed to produce good-quality information about the results of the procedure. These results should include measuring any improvement in patients' quality of life, and the benefits and risks of ACI over a long period of time. This guidance replaces TA16 Knee joints (defective) - autologous cartilage transplantation.		
May-05	TA90	Vascular disease - clopidogrel and dipyridamole	This guidance has been replaced by TA210 Vascular disease - clopidogrel and dipyridamole	clopidogrel and dipyridamole	yes
May-05	TA91	Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)	The guidance issued by NICE only applies to paclitaxel, PLDH and topotecan. NICE has issued the following recommendations for the treatment of women with advanced ovarian cancer.	paclitaxel, topotecan, pegylated liposomal doxorubicin hydrochloride.	Condition not treated at RFL
Jul-05	TA92	Tooth decay - HealOzone	NICE has said that HealOzone is not recommended as a treatment for specific types of tooth decay, unless it is being used in a clinical trial. The reason for this was that there was not enough reliable evidence that HealOzone is more effective than existing treatments for decay of the biting surfaces and roots of the teeth.		
Aug-05	TA93	Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed	This guidance has been replaced by CG131 Colorectal cancer	irinotecan, oxaliplatin and raltitrexed	Guidance replaced
Jan-06	TA94	Cardiovascular disease - statins	This guidance relates only to the initiation of statin therapy in adults with clinical evidence of cardiovascular disease (CVD) and in adults considered to be at risk of CVD. It assumes that other strategies for managing CVD risk are being appropriately considered when initiating statin therapy. The guidance does not include specific advice for genetic dyslipidaemias (for example, familial hypercholesterolaemia). The guidance relates only to the use of statins within their licensed indications.	statins	Yes
Jan-06	TA95	Arrhythmia - implantable cardioverter defibrillators (ICDs) (review)	This appraisal does not cover the use of implantable defibrillators for non-ischaemic dilated cardiomyopathy. ICDs are recommended for patients in the following categories, 'Secondary prevention', 'Primary prevention'. This guidance replaces TA11 Arrhythmias - implantable cardioverter defibrillators (ICDs)		
Feb-06	TA96	Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alfa-2a	NICE has made the following recommendations about the use of adefovir dipivoxil and peginterferon alfa-2a to treat chronic hepatitis B. These recommendations do not apply to people who are also infected with hepatitis C or D, or HIV.	adefovir dipivoxil, peginterferon alfa-2a, lamivudine	Yes
Feb-06	TA97	Depression and anxiety - computerised cognitive behavioural therapy (CCBT)	NICE has made the following recommendations about the use of computerised cognitive behavioural therapy (CCBT) to treat depression and anxiety. It recommends using: Beating the Blues for people with mild and moderate depression, and: FearFighter for people with panic and phobia. This guidance replaces TA51 Depression and anxiety - computerised cognitive behaviour therapy (CCBT).		
Mar-06	TA98	Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review)	If a child or adolescent needs treatment with medication for ADHD, methylphenidate, atomoxetine and dexamfetamine are all recommended as possible choices.	methylphenidate, atomoxetine and dexamfetamine	Yes
Apr-06	TA99	Renal transplantation - immunosuppressive regimens for children and adolescents	NICE has made recommendations about the use of immunosuppressive drugs in children and adolescents receiving kidney transplants.	Basiliximab and daclizumab, Tacrolimus, Mycophenolate mofetil, Mycophenolate sodium, Sirolimus.	yes
Apr-06	TA100	Colon cancer (adjuvant) - capecitabine and oxaliplatin	Capecitabine and oxaliplatin are recommended as possible adjuvant treatments after surgery for stage III (Dukes' C) colon cancer, when used in the following ways: capecitabine on its own; oxaliplatin together with 5-fluorouracil and folinic acid.	Capecitabine, oxaliplatin, 5-fluorouracil and folinic acid	
Jun-06	TA101	Prostate cancer (hormone-refractory) - docetaxel	Docetaxel is recommended as a possible treatment for men with hormone-refractory metastatic prostate cancer. It should be given only if the man is well enough to care for himself with occasional assistance. Treatment should be stopped at the end of a planned course of up to 10 cycles (or 'rounds') of docetaxel. The treatment should be stopped early if the man experiences serious side effects, or if the disease is getting worse. NICE does not recommend using docetaxel again if the disease comes back after the first course of treatment has finished.	Docetaxel	yes
Jul-06	TA102	Conduct disorder in children - parent-training/education programmes	NICE recommends group-based parent-training/education programmes in the management of children with conduct disorders. Individual-based programmes are only recommended where the family's needs are too complex for a group-based programme.		

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Jul-06	TA103	Psoriasis - efalizumab and etanercept	Etanercept should be offered as an option for treating adults with severe plaque psoriasis when: other treatments haven't worked (for example, drugs given by injection or orally, that is, by mouth), or these other treatments cause a reaction which means that the person shouldn't continue taking them, or the person has another condition or uses another medicine that means they should not take these other treatments. Efalizumab: The European Medicines Agency (EMA), the European Union (EU) body which is responsible for monitoring the safety of medicines, has withdrawn the marketing authorisation for MerckSerono's psoriasis drug efalizumab (Raptiva). The EMA's Committee for Medicinal Products for Human Use has reviewed possible links between the drug and a rare but deadly brain infection and said the benefits of efalizumab no longer outweigh its risks, because of safety concerns, notably the occurrence of progressive multifocal leukoencephalopathy.	Etanercept and Efalizumab	Yes (efalizumab no longer available)
Jul-06	TA104	Psoriatic arthritis - etanercept and infliximab	This guidance has been replaced by TA199 Psoriatic arthritis - etanercept, infliximab and adalimumab. Erratum:1.3 Infliximab, within its licensed indications, is recommended for the treatment of adults with severe active psoriatic arthritis if, under the circumstances outlined in section 1.1, treatment with an anti-TNF (tumour necrosis factor) agent is considered appropriate and the person has been shown to be intolerant of, or have contraindications to, treatment with etanercept or has major difficulties with self administered injections.	infliximab, infliximab	
Aug-06	TA105	Colorectal cancer - laparoscopic surgery (review)	Laparoscopic surgery (including laparoscopically assisted surgery) is recommended as an alternative to open surgery for people with colorectal cancer if: both laparoscopic and open surgery are suitable for the person and their condition; their surgeon has been trained in laparoscopic surgery for colorectal cancer and performs the operation often enough to keep his or her skills up to date.		
Aug-06	TA106	Hepatitis C - peginterferon alfa and ribavirin	This guidance has been partially updated by Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C' (NICE technology appraisal guidance 200). See the guidance and the quick reference guide for more information. Peginterferon alfa and ribavirin are recommended as possible treatments for people with mild chronic hepatitis C if they are suitable for the person and are used in these ways.	Peginterferon alfa and ribavirin	yes
Aug-06	TA107	Breast cancer (early) - trastuzumab	Trastuzumab treatment should be offered as an option for women with early-stage HER2-positive breast cancer after they have had surgery and chemotherapy (and sometimes radiotherapy). Trastuzumab should be given once every 3 weeks for 12 months, or until the breast cancer comes back, whichever is sooner.	Trastuzumab	yes
Sep-06	TA108	Breast cancer (early) - paclitaxel	Paclitaxel is not recommended as an option for the adjuvant treatment of women with early node-positive breast cancer. Because Paclitaxel within its licensed indication is not recommended for the adjuvant treatment of women with early node-positive breast cancer then it is not considered to have any significant cost implications. Therefore, no costing template has been developed for this appraisal.	Paclitaxel	No
Sep-06	TA109	Breast cancer (early) - docetaxel	Docetaxel (given with doxorubicin and cyclophosphamide) is recommended as a possible adjuvant treatment for women with early node-positive breast cancer.	Docetaxel, doxorubicin and cyclophosphamide	yes
Sep-06	TA110	Follicular lymphoma - rituximab	This guidance has been replaced by TA243 Follicular lymphoma - rituximab (review)	rituximab	guidance replaced
Sep-06	TA111	Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine	This guidance has been updated and replaced by TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine.	donepezil, galantamine, rivastigmine and memantine.	yes
Nov-06	TA112	Breast cancer (early) - hormonal treatments	Anastrozole, exemestane and letrozole are recommended as possible treatments for women who have a type of breast cancer called early oestrogen-receptor-positive breast cancer and have been through the menopause. Anastrozole, exemestane or letrozole may be given as an 'extra' treatment (called an adjuvant treatment), after the woman has had an operation to remove the cancer, to help to stop the cancer coming back.	Anastrozole, exemestane and letrozole	yes
Dec-06	TA113	Diabetes (type 1 and 2) - inhaled insulin	In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications.	Exubera	no
Jan-07	TA114	Drug misuse - methadone and buprenorphine	Methadone and buprenorphine (given as a tablet or a liquid) are recommended as treatment options for people who are opioid dependent.	Methadone and buprenorphine	Yes
Jan-07	TA115	Drug misuse - naltrexone	Naltrexone is recommended as a treatment option for people who have been opioid dependent but who have stopped using opioids and who are highly motivated to stay free from the drugs in an abstinence programme. It should only be given to people who have been told about the problems associated with treatment, and with proper supervision. Treatment with naltrexone should be given as part of a support programme to help the person manage their opioid dependence.	Naltrexone	yes

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Jan-07	TA116	Gemcitabine for the treatment of metastatic breast cancer	Gemcitabine, which is combined with another medicine called paclitaxel to treat metastatic breast cancer in situations where other treatments could also be used as alternatives. Other treatments that doctors could use in the same situation are a medicine called docetaxel (given on its own) and docetaxel combined with another medicine called capecitabine.	Gemcitabine and capecitabine	
Jan-07	TA117	Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy	Cinacalcet is not generally recommended for treating people on dialysis which have hyperparathyroidism because of their kidney disease. However, it is recommended for people on dialysis who: have very high levels of parathyroid hormone in their blood that can't be lowered by other treatments, and cannot have an operation to remove the parathyroid glands (a parathyroidectomy), because of the risk involved.	Cinacalcet	yes
Jan-07	TA118	Colorectal cancer (metastatic) - bevacizumab and cetuximab	This guidance has been partially updated by TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review). Bevacizumab in combination with 5-fluorouracil plus folinic acid, with or without irinotecan, is not recommended for people with metastatic colorectal cancer who have not been treated before.	Bevacizumab and cetuximab	no
Feb-07	TA119	Fludarabine monotherapy for the first line treatment of chronic lymphocytic leukaemia	Fludarabine given on its own is not recommended as an initial treatment for people with chronic lymphocytic leukaemia (CLL)	Fludarabine	yes
May-07	TA120	Heart Failure - cardiac resynchronisation	Cardiac resynchronisation therapy using a pacing device is recommended as a possible treatment for people with heart failure where certain circumstances apply ( please see TA120 in full for further details).		
Jun-07	TA121	Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide	Carmustine implants are recommended as a possible treatment for people with newly diagnosed high -grade glioma only if 90% or more of their tumour has been removed. People should have carmustine implants only at specialist treatment centres under the care of a team of experts, as described in "improving outcomes for people with brain and other central nervous system tumours"	Carmustine implants and temozolomide.	Condition not treated at RFL
Jun-07	TA122	Ischaemic stroke ( acute ) - alteplase	This guidance has been replaced by TA264 Stroke ( acute ischaemic ) - alteplase		replaced
Jul-07	TA123	Smoking cessation - varenicline	Varenicline is recommended as a possible treatment to help smokers who have said they want to stop smoking. Varenicline should normally be used only as part of a programme that includes advice from a healthcare professional or other types of support.	Varenicline	yes
Aug-07	TA124	Lung Cancer (non-small-cell) - pemetrexed	Pemetrexed has now been recommended for the first-line treatment of non-small-cell lung cancer. TA 124 applies to patients who have had prior chemotherapy.	Pemetrexed	yes
Aug-07	TA125	Psoriatic arthritis (moderate to severe) adalimumab	This guidance has been replaced by TA 199 Psoriatic arthritis etanercept, infliximab and adalimumab	adalimumab	
Aug-07	TA126	Rheumatoid arthritis (refractory) - rituximab	This guidance has been replaced by TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor	rituximab	
Aug-07	TA127	Natalizumab for the treatment of adults with highly active relapsing - remitting multiple sclerosis	Natalizumab is recommended as a possible treatment for people with rapidly evolving severe relapsing -remitting multiple sclerosis.	Natalizumab	yes
Sep-07	TA128	Haemorrhoid - stapled Haemorrhoidopexy	Stapled haemorrhoidopexy is recommended as a possible treatment for people with prolapsed internal haemorrhoids; it is carried out with a circular stapler designed for treating haemorrhoids in this way. Surgery is considered to be a suitable treatment for their condition.		
Oct-07	TA129	Multiple myeloma - bortezomib	This guidance recommends bortezomib monotherapy as a possible treatment for progressive multiple myeloma for people whose multiple myeloma has relapsed for the first time after having one treatment	Bortezomib	yes
Oct-07	TA130	Rheumatoid arthritis - adalimumab, etanercept and infliximab	This guidance recommends adalimumab, etanercept and infliximab as possible treatments for people with rheumatoid arthritis who: have already tried methotrexate and another disease-modifying anti-rheumatic drug (DMARD), and have "active " rheumatoid arthritis, as assessed by a rheumatologist on two separate occasions. People who are treated with adalimumab, etanercept or infliximab should normally also be given methotrexate. If methotrexate does not suit them, they may be given adalimumab or etanercept on its own.	Adalimumab, etanercept and infliximab.	yes
Nov-07	TA 131	Asthma ( in children ) - corticosteroids.	If inhaled corticosteroids are appropriate for children aged under 12 years who have chronic asthma, the least expensive product that is suitable for the individual child should be used. If both an inhaled corticosteroid and a long-acting beta-2 agonist are needed, then a combination device that contains both medicines may be used. The decision to use a combination device should be based on the individual child and their asthma. If a combination device is chosen, the least expensive device that is suitable for the individual child should be used.	corticosteroids	yes

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Nov-07	TA132	Hypercholesterolaemia - ezetimibe	Ezetimibe is recommended as a possible treatment for adults with primary (heterozygous-familial and non-familial) hypercholesterolaemia in the following circumstances. Ezetimibe can be taken on its own by a person who would normally be given a statin to treat their condition but can't because the person has a condition or takes another medicine that interferes with how the statin works, or because the statin is likely to cause side effects. Ezetimibe can be taken at the same time as a person's usual statin rather than changing to a new statin when cholesterol levels are not low enough despite increasing the dose of the statin, or if a person is unable to try higher doses of the statin because it is likely to cause side effects.	Ezetimibe	yes
Nov-07	TA133	Asthma (uncontrolled) - omalizumab	Omalizumab is recommended as a possible treatment for adults and young people over 12 years with severe persistent allergic asthma when all of the following circumstances apply. When the person's asthma is still severe and unstable despite best efforts to control under drs management. when the person has stopped smoking. When the person has allergic asthma. This should be confirmed by checking past symptoms and skin testing for allergies. When eh person has had at least two asthma attacks within the past year that have needed admission to the hospital, or when the person has had three or more severe asthma attacks within the past year , one of which has needed admission to hospital and the other two have needed additional treatment in an accident and emergency dept	Omalizumab	yes
Jan-08	TA134	Psoriasis - infliximab	Infliximab is recommended as a possible treatment for adults with plaque psoriasis only if their condition is very severe and their condition has not improved with other treatments such as ciclosporin, methotrexate or PUVA (psoralen and long-wave ultraviolet radiation), or they have had had side effects with these in the past or there is a medical reason why they should not be given these treatments.	Infliximab	yes
Jan-08	TA135	Pemetrexed disodium for the treatment of mesothelioma	Pemetrexed is recommended as a possible treatment for malignant pleural mesothelioma in people with advance disease \ who cancer is not suitable for surgical resection \ who have a WHO performance status of 0.	Pemetrexed disodium	yes
Feb-08	TA136	Structural neuroimaging in first-episode psychosis	Structural neuroimaging, using methods called magnetic resonance imaging (MRI) or computed axial tomography (CT) scanning, is not recommended for use routinely to examine all people who have had a first episode of psychosis.		
Feb-08	TA137	Lymphoma (follicular non-Hodgkin's) - rituximab	this guidance replaces NICE technology appraisal guidance 37 issued in March 2002. The review and re-appraisal of the use of rituximab for the treatment of relapsed or refractory stage III or iv follicular non-Hodgkin's lymphoma has resulted in a change in the guidance. In people with relapsed stage III or IV follicular non-Hodgkin's lymphoma, rituximab is now an option in combination with chemotherapy to induce remission or alone as maintenance therapy during remission. Rituximab monotherapy is also an option for people with relapsed or refractory disease when all alternative treatment options have been exhausted.	Rituximab	yes
Mar-08	TA138	Asthma (in adults) - corticosteroids	This guidance cover the use of inhaled corticosteroids to treat adults and children aged 12 years and over with chronic asthma in the NHS in England and Wales	Corticosteroids	yes
Mar-08	TA139	Sleep Apnoea - CPAP	This guidance is the full technology appraisal on sleep apnoea - continuous positive airway pressure		
Apr-08	TA140	Ulcerative colitis (subacute manifestations) - infliximab	Infliximab is not recommended for people with subacute, moderately to severely active ulcerative colitis. Subacute ulcerative colitis is defined as ulcerative colitis that would normally be managed without needing to stay in hospital overnight or having urgent surgery.	infliximab	On formulary but not for this indication
Apr-08	TA141	Rheumatoid Arthritis (refractory) - abatacept	This guidance has been replaced by TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor.	abatacept	replaced
May-08	TA142	Anaemia ( cancer-treatment induced) erythropoietin and darbepoetin	Erythropoietin analogues with iron injections are recommended as a possible treatment for anaemia caused by cancer treatment in specific cases	Erythropoietin and darbepoietin	yes
May-08	TA143	Ankylosign spondylitis - adalimumab, etanercept and infliximab	Adalimumab or etanercept are recommended as possible treatments for people with severe ankylosing spondylitis under particular conditions	adalimumab, etanercept and infliximab	yes
Jun-08	TA144	Obesity - rimonabant	Withdrawn		
Jun-08	TA145	Head and neck cancer - cetuximab	Cetuximab in combination with radiotherapy is recommended as a possible treatment for people with locally advance squamous cell cancer of the head and neck in particular situations	Cetuximab	Condition not treated at RFL
Jun-08	TA146	Adalimumab for the treatment of psoriasis under certain conditions ( see full TA for guidance	Adalimumab is recommended as a possible treatment for adults with plaque psoriasis under certain conditions - see NICE TA for further details	Adalimumab	yes
Jun-08	TA147	Breast Cancer (advanced and metastatic) bevacizumab	This guidance has been replaced by TA214, February 2011, "bevacizumab in combination with a taxane for the first-line treatment of metastatis breast cancer		

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Jun-08	TA148	Lung cancer (non-small-cell) - bevacizumab (terminated appraisal)	NICE is unable to recommend the use in the NHS of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) because no evidence submission was received from the manufacturer or sponsor of the technology.	bevacizumab	no
Jun-08	TA149	Glioma (recurrent) - carmustine implants (terminated appraisal)	NICE is unable to recommend the use in the NHS of carmustine implants as an adjunct to surgery in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated because no evidence submission was received from the manufacturer or sponsor of the technology.	carmustine implants .	No
Jun-08	TA150	Colorectal cancer (metastatic) - cetuximab	This guidance has been replaced by TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)	cetuximab	
Jul-08	TA151	Diabetes - insulin pump therapy	This guidance replaced NICE Technology appraisal guidance 57 issued in February 2003.	insulin	Yes
Jul-08	TA152	Coronary artery disease - drug-eluting stents	Drug-eluting stents are recommended as a possible treatment for people with coronary artery disease only if (1) the artery to be treated is less than 3mm in diameter or the affected section of the artery is longer than 15mm, and the additional cost of the drug-eluting stents over bare-metal stents is £300 or less.		
Aug-08	TA153	Hepatitis B - entecavir	Entecavir is recommended as a possible treatment for people with chronic hepatitis B	Entecavir	Yes
Aug-08	TA154	Hepatitis B - telbivudine	Telbivudine is not recommended for people with chronic hepatitis B. -see NICE TA for full guidance	Telbivudine	No
Aug-08	TA155	Macular degeneration (age-related) ranibizumab and pegaptanib	This guidance has been re-issued after a change to the patient access scheme in May 2012. Recommendation 1.1 and section 5.3 of the guidance have been updated (May 2012)	Pegaptanib and ranibizumab	Pegaptanib -NO, ranibizumab - yes
Aug-08	TA156	Pregnancy (rhesus negative women) - routine anti- D (review)	Routine antenatal anti-D prophylaxis is recommended as a treatment option for all pregnant women who are RhD negative and who are not known to be 'sensitised'. When a decision has been made to give routine antenatal anti-D prophylaxis, the treatment with the lowest cost should be used. This should take into account the costs of both obtaining and giving the treatment.	antenatal anti-D prophylaxis	
Sep-08	TA157	Venous thromboembolism - dabigatran	Dabigatran etexilate is recommended as a possible treatment to reduce the risk of venous thromboembolism in adults who have surgery to replace their hip or knee joint.	Dabigatran etexilate	Yes
Sep-08	TA158	Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir	NICE has said that its recommendations about oseltamivir and zanamivir should not reduce efforts to give vaccination (also called the flu jab) to people for whom it is recommended in national guidelines.	oseltamivir, amantadine and zanamivir	Yes
Oct-08	TA159	Pain (chronic neuropathic or ischaemic) - spinal cord stimulation	Spinal cord stimulation is recommended as a possible treatment for adults with chronic pain of neuropathic origin		
Nov-08	TA160	Osteoporosis - primary prevention	Whether or not a postmenopausal woman with osteoporosis is offered one of these drugs to prevent bone fractures will depend on her	Alendronate, etidronate, risedronate, raloxifene, and strontium ranelate	Yes
Nov-08	TA161	Osteoporosis - secondary prevention including strontium ranelate	This guidance replaced TA87 Osteoporosis - secondary prevention.	Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide.	Yes
Nov-08	TA162	Lung cancer (non-small-cell) - erlotinib	The patient access scheme for erlotinib has changed. The DoH and the manufacturer have agreed that erlotinib will be offered to the NHS under a patient access scheme (as revised in 2012), which makes erlotinib available with a discount on the list price applied to original invoices. The discount applies for all indications of erlotinib.	Erlotinib	Yes
Dec-08	TA163	Ulcerative colitis (acute exacerbations) - infliximab	Infliximab is recommended as a possible treatment for people with acute, severely active ulcerative colitis only if (a) ciclosporin is considered inappropriate for them or (2) they are taking part in a research study	Infliximab	Yes
Dec-08	TA164	Hyperuricaemia - febuxostat	Febuxostat is recommended as a possible treatment for chronic hyperuricaemia in people with gout	Febuxostat	In progress
Nov-08	TA165	Organ preservation (renal) - machine perfusion and static storage	Various methods of storage are listed in the full TA guidance	Belzer UW storage solution or Marshall's hypertonic citrate solution	
Jan-09	TA166	Hearing impairment - cochlear implants	See Full TA for assessment treatment details		
Feb-09	TA167	Abdominal aortic aneurysm - endovascular stent-grafts	See full TA for assessment for treatment options		
Feb-09	TA168	Influenza - zanamivir, amantadine and oseltamivir	NICE has said that its recommendations about oseltamivir and zanamivir should not reduce efforts to give vaccination (also called the flu jab) to people for whom it is recommended in national guidelines. See full TA for further details	zanamivir, amantadine and oseltamivir	Yes
Mar-08	TA169	Renal Cell carcinoma - sunitinib	Sunitinib is recommended as a possible first drug treatment for people with advanced and/or metastatic renal cell carcinoma if certain criteria is met.	Sunitinib	Yes
Apr-09	TA170	Venous thromboembolism - rivaroxaban	Rivaroxaban is recommended as an option	Rivaroxaban	Yes
Jun-09	TA171	Multiple myeloma - lenalidomide	Lenalidomide (with dexamethasone) is recommended as a possible treatment for people with multiple myeloma who have already had at least two other treatments.	Lenalidomide	Yes

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Jun-09	TA172	Head and neck cancer ( squamous cell carcinoma) - cetuximab	Cetuximab in combination with platinum-based chemotherapy is not recommended for people with recurrent and / or metastatic squamous cell cancer of the head and neck.	Cetuximab	No- condition not treated at RFL
Jul-09	TA173	Hepatitis B - tenofovir disoproxil fumarate	Tenofovir is recommended as a possible treatment for people with chronic hepatitis B	Tenofovir	Yes
Jul-09	TA174	Leukaemia (chronic lymphocytic first line) - rituximab	Rituximab is recommended as a possible first treatment for people with chronic lymphocytic leukaemia in whom fludarabine in combination with cyclophosphamide are appropriate.	Rituximab, fludarabine and cyclophosphamide	Yes
Jul-09	TA175	Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal)	NICE is unable to recommend the use of gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer because no evidence submission was received from the manufacturer or sponsor of the technology	Gefitinib - terminated appraisal	No
Aug-09	TA176	Colorectal cancer (first line) - cetuximab	Cetuximab given with 5-fluorouracil, folinic acid and oxaliplatin is recommended as a possible first treatment for people with metastatic colorectal cancer under certain criteria.	Cetuximab, 5-fluorouracil, folinic acid, and oxaliplatin.	Yes
Aug-09	TA177	Eczema (chronic) - alitretinoin	Alitretinoin is recommended as a possible treatment for people with severe chronic hand eczema if certain criteria is met.	Alitretinoin	Yes
Aug-09	TA178	Renal cell carcinoma	Bevacizumab, sorafenib and temsirolimus are not recommended as first drug treatments for people with advanced and / or metastatic renal cell carcinoma.	Bevacizumab, sorafenib and temsirolimus	No
Sep-09	TA179	Gastrointestinal stromal tumours - sunitinib	Sunitinib is recommended as a possible treatment for people with unresectable or metastatic malignant gastrointestinal stromal tumour if they have already tried imatinib treatment but it has not worked or was not suitable.	Sunitinib, imatinib	Condition not treated at RFL
Sep-09	TA180	Psoriasis - ustekinumab	Ustekinumab is recommended as a possible treatment for people with plaque psoriasis under certain conditions	Ustekinumab	Yes
Sep-09	TA181	Lung cancer (non-small-cell, first line treatment) pemetrexed	Pemetrexed is recommended as a possible treatment for locally advanced or metastatic non-small-cell cancer (NSCLS) under certain conditions.	Pemetrexed	Yes
Oct-09	TA182	Acute coronary syndrome - prasugrel	Prasugrel in combination with aspirin is recommended as an option for preventing blockages in the arteries of people with acute coronary syndromes who are having percutaneous coronary intervention under certain criteria.	Prasugrel	Yes
Oct-09	TA183	Cervical cancer (recurrent) - topotecan	Topotecan in combination with cisplatin is recommended as a possible treatment for women with recurrent or Stage IVB cervical cancer only if they have not received cisplatin before.	Topotecan and Cisplatin	
Nov-09	TA184	Lung cancer (small-cell) - Topotecan	Oral topotecan is recommended as a possible treatment for people with relapsed small-cell lung cancer under certain criteria .	Topotecan	Yes
Feb-10	TA185	Soft Tissue sarcoma - Trabectedin	Trabectedin is recommended as a possible treatment for people with advanced soft tissue sarcoma.	Trabectedin	No- sarcoma not treated at RFL
Feb-10	TA186	Rheumatoid arthritis - certolizumab pegol	Certolizumab pegol is recommended as a possible treatment for people with rheumatoid arthritis under certain criteria.	Certolizumab pegol	Yes
May-10	TA187	Crohn's disease - Infliximab (review and adalimumab (review of TA40)	This guidance replaces ' NICE technology appraisal guidance 40' issued in April 2002. Infliximab and adalimumab are recommended as treatment options for severe active Crohns disease	Tumour necrosis factor alpha (TNF) inhibitors (adalimumab, and infliximab )	Yes
May-10	TA188	Human growth hormone (somatropin) for the treatment of growth failure in children (review)	NICE recommends human growth hormone (somatropin) as a possible treatment for some children with growth failure.	Somatropin	Yes
May-10	TA189	Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)	Nice does not recommend sorafenib for people with advance hepatocellular carcinoma.	Sorafenib	No
Jun-10	TA190	Lung cancer (non-small-cell) - pemetrexed (maintenance)	NICE recommends pemetrexed as a possible maintenance treatment for some people with non-small-cell lung under certain criteria.	Pemetrexed	Yes
Jul-10	TA191	Gastric cancer ( advanced ) - capecitabine	NICE recommends capecitabine taken with platinum-containing drugs, for some people with stomach cancer.	Capecitabine, Platinum-containing drugs	
Jul-10	TA192	Lung cancer (non-small-cell, first line) gefitinib	NICE recommends gefitinib as a possible first treatment for some people with locally advanced or metastatic non-small-cell lung cancer under certain criteria. .	Gefitinib	Yes
Jul-10	TA193	Leukaemia (chronic lymphocytic, relapsed) rituximab	NICE recommends taking rituximab, fludarabine and cyclophosphamide together under certain criteria.	Rituximab, Fludarabine and cyclophosphamide	Yes
Jul-10	TA194	Bone loss (therapy-induced) in non-metastatic prostate cancer- denosumab ( terminated appraisal)	NICE is unable to recommend the use of denosumab for the treatment of therapy-induced bone loss in people with non-metastatic prostate cancer because no evidence submission was received from the manufacturer or sponsor of the technology	Denosumab- terminated appraisal	No
Aug-10	TA195	Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor	This guidance replaces NICE TA guidance 126 and 141 issued in Aug 2007 and April 2008 respectively. It also replaces the remaining recommendations in NICE technology appraisal guidance 36 issued in March 2002.		Yes
Aug-10	TA196	Gastrointestinal stromal tumours - imatinib (adjuvant)	NICE does not recommend imatinib as an adjuvant treatment for people after surgical removal of a GIST	Imatinib	Condition not treated at RFL

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Aug-10	TA197	Atrial fibrillation - dronedarone	Following safety concerns, the European Medicines Agency (EMA) has amended the marketing authorisation for dronedarone. The therapeutic indication is now more restricted than that originally appraised in NICE technology appraisal guidance 197. For more information, see the summary of product characteristics for dronedarone.	Dronedarone	No
Aug-10	TA198	Rheumatoid arthritis - Tocilizumab	Replaced by TA247		
Aug-10	TA199	Psoriatic arthritis - Etanercept, Inflixumab and Adalimumab			Yes
Sep-10	TA200	Hepatitis C - peginterferon alfa and ribavirin	This guidance should be read in conjunction with the following NICE guidance, TA75 and TA106	peginterferon alfa and ribavirin	Yes
Oct-10	TA201	Asthma (in children) - omalizumab	This guidance relates to using omalizumab to treat children aged 6 - 11 years with severe persistent allergic asthma.	Omalizumab	Yes
Oct-10	TA202	Chronic lymphocytic leukaemia - ofatumumab	NICE does not recommend ofatumumab for people with chronic lymphocytic leukaemia that is refractory to treatment with fludarabine and alemtuzumab.	Ofatumumab	No
Oct-10	TA203	Diabetes (type 2) - liraglutide	NICE recommends liraglutide taken at a dose of 1.2mg once a day as a possible treatment for some people with type 2 diabetes mellitus. However, NICE does not recommend liraglutide taken at a higher dose to 1.8mg once a day.	Liraglutide	Yes
Oct-10	TA204	Osteoporotic fractures - denosumab	NICE recommends denosumab as a possible treatment for preventing bone fractures in some postmenopausal women with osteoporosis. See full TA for further details.	Denosumab	Yes
Oct-10	TA205	Thrombocytopenic purpura - eltrombopag	NICE does not recommend eltrombopag for people with chronic immune (idopathic) thrombocytopenic purpura.	Eltrombopag	Yes- review in progress
Oct-10	TA206	Lymphoma (non-Hodgkin's) - bendamustine (terminated appraisal)	NICE is unable to recommend the use in the NHS of bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen because no evidence submission was received from the manufacturer or sponsor of the technology.	Bendamustine - terminated appraisal.	No
Oct-10	TA207	Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma(terminated appraisal)	Nice is unable to recommend the use in the NHS of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma because no evidence submission was received from the manufacturer or sponsor of the technology.	Temsirolimus- terminated appraisal	No
Nov-10	TA208	Gastric cancer (HER2-positive metastatic) - trastuzumab	NICE recommends trastuzumab as a possible treatment for some people with a type of HER2-positive metastatic gastric cancer (adenocarcinoma)	Trastuzumab	Yes
Nov-10	TA209	Gastrointestinal stromal tumours (unresectable / Metastatic Imatinib)	Nice does not recommend imatinib at a dose of 600 or 800mg a day for people with unresectable and / or metastatic GISTs whose disease has got worse after treatment with imatinib at a dose of 400mg a day.	Imatinib (high dose)	Condition not treated at RFL
Dec-10	TA210	Vascular disease - clopidogrel and dipyridamole	This guidance replaces NICE technology appraisal guidance 90 issued in May 2005. The review and re-appraisal of clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events has resulted in a change in the guidance under certain criteria.	Clopidogrel and dipyridamole	Yes
Dec-10	TA211	Constipation (women) - prucalopride	NICE recommends prucalopride as a possible treatment for women with chronic constipation, under certain criteria.	Prucalopride	Yes
Dec-10	TA212	Colorectal cancer (metastatic) - bevacizumab	NICE does not recommend bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for people with metastatic colorectal cancer.	Bevacizumab	No
Jan-11	TA213	Schizophrenia - aripiprazole	NICE recommends aripiprazole as a possible treatment for some people aged 15 - 17 year with schizophrenia under certain conditions.	Aripiprazole	Yes
Feb-11	TA214	Breast cancer - bevacizumab (in combination with a taxane)	NICE does not recommend bevacizumab in combination with a taxane as first treatment for people with metastatic breast cancer.	Bevacizumab and taxanes	No
Feb-11	TA215	Renal cell carcinoma (first line metastatic) - pazopanib	NICE recommends pazopanib as a possible treatment for some people with renal cell carcinoma under certain conditions.	Pazopanib	Yes
Feb-11	TA216	Leukaemia (lymphocytic) - bendamustine	NICE recommends bendamustine as a possible treatment for some people with chronic lymphocytic leukaemia of Binet stage B or C.	Bendamustine	Yes
Mar-11	TA217	Alzheimer's disease - donepezil, galantamine, rivastigmine, and memantine	This guidance replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009)	Donepezil, galantamine, rivastigmine, and memantine	Yes
Mar-11	TA218	Myelodysplastic syndromes - azacitidine	NICE recommends azacitidine as a possible treatment for some adults with myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia.	Azacitidine	Yes
Apr-11	TA219	Everolimus for the second-line treatment of advanced renal cell carcinoma	NICE does not recommend everolimus as a second treatment for people with advanced renal cell carcinoma.	Everolimus	No
Apr-11	TA220	Psoriatic arthritis - golimumab	NICE recommends golimumab as a possible treatment for people with psoriatic arthritis in the same circumstances as other drugs for this condition.	Golimumab	Yes
Apr-11	TA221	Thrombocytopenic purpura - romiplostim	NICE recommends Romiplostim for the treatment of adults with chronic immune idiopathic thrombocytopenia purpura under certain conditions.	Romiplostim	Yes
Apr-11	TA222	Ovarian cancer (relapsed) - Trabectedin	NICE does not recommend trabectedin taken with pegylated liposomal doxorubicin hydrochloride for women with relapsed platinum-sensitive ovarian cancer.	Trabectedin	No condition not treated at RFL

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
May-11	TA223	Peripheral arterial disease - cilostazol, naftidofuryl oxalate, pentoxifylline and inositol nicotinate	Naftidofuryl oxalate is recommended as an option for the treatment of intermittent claudication in people with peripheral arterial disease for whom vasodilator therapy is considered appropriate after taking into account other treatment options. Treatment with naftidofuryl oxalate should be started with the least costly licensed preparation. Cilostazol, pentoxifylline and inositol nicotinate are not recommended for the treatment of intermittent claudication in people with peripheral arterial disease.	Cilostazol, naftidofuryl oxalate, pentoxifylline and inositol nicotinate	Naftidofuryl - Yes. Others NO.
Jun-11	TA224	Rheumatoid arthritis (methotrexate-naïve) - golimumab (terminated appraisal)	NICE is unable to recommend the use in the NHS of golimumab for the treatment of methotrexate-naïve rheumatoid arthritis because no evidence submission was received from the manufacturer or sponsor of the technology.	Golimumab- terminated appraisal	No
Jun-11	TA225	Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab	NICE recommends golimumab as a possible treatment for some adults with rheumatoid arthritis in the same circumstances as other drugs for the condition.	Golimumab, Methotrexate	Yes
Jun-11	TA226	Lymphoma (follicular non-Hodgkin's) - rituximab	NICE recommends rituximab as a possible treatment to maintain remission in people with follicular non-Hodgkin's.	Rituximab.	Yes
Jun-11	TA227	Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)	NICE does not recommend erlotinib as maintenance treatment after chemotherapy that contains platinum for people with locally advanced or metastatic non-small-cell lung cancer.	Erlotinib	No
Jul-11	TA228	Multiple myeloma (first line) - bortezomib and thalidomide	NICE recommends bortezomib and thalidomide as possible first treatments for some people with multiple myeloma.	Bortezomib and thalidomide	yes
Jul-11	TA229	Macular oedema (retinal vein occlusion) - dexamethasone	NICE recommends dexamethasone intravitreal implant as a possible treatment for some people with macular oedema due to retinal vein occlusion.	Dexamethasone intravitreal	Yes
Jul-11	TA230	Myocardial infarction (persistent ST-segment elevation) - bivalirudin.	NICE recommends bivalirudin as a possible treatment for adults with STEMI who are having percutaneous coronary intervention.	Bivalirudin	Yes
Jul-11	TA231	Depression - agomelatine (terminated appraisal)	NICE is unable to recommend the use in the NHS of agomelatine for the treatment of major depressive episodes because no evidence submission was received from the manufacturer or sponsor of the technology.	Agomelatine- terminated appraisal	No
Jul-11	TA232	Epilepsy (partial) - retigabine (adjuvant)	NICE recommends retigabine as a possible add-on treatment for partial onset seizures with or without secondary generalisation in some people with epilepsy.	Retigabine	In progress
Aug-11	TA233	Ankylosing spondylitis - golimumab	NICE recommends golimumab as a possible treatment for some adults with severe, active ankylosing spondylitis in the same circumstances as other drugs for the condition.	Golimumab	Yes
Aug-11	TA234	Rheumatoid arthritis - abatacept (2nd line)	NICE does not recommend abatacept, taken with methotrexate, for adults with moderate to severe active rheumatoid arthritis when one or more disease-modifying anti-rheumatic drugs, including methotrexate, have not worked.	Abatacept	No
Oct-11	TA235	Osteosarcoma - mifamurtide	NICE recommends mifamurtide as a possible treatment for some children adolescents and young adults with osteosarcoma.	Mifamurtide	Condition not treated at RFL
Oct-11	TA236	Acute coronary syndromes - ticagrelor	NICE recommends ticagrelor combined with low-dose aspirin for up to a year as a possible treatment for some people with acute coronary syndromes.	Ticagrelor, low dose aspirin	Yes
Nov-11	TA237	Macular oedema (diabetic) - ranibizumab	This guidance has been replaced by TA274 Macular odema - ranibizumab, see appropriate TA for further details.	Ranibizumab	Yes
Dec-11	TA238	Arthritis (juvenile idiopathic, systemic - tocilizumab	NICE recommends tocilizumab as a possible treatment for some children and young people with systemic juvenile idiopathic arthritis.	Tocilizumab	Condition not treated at RFL
Dec-11	TA239	Breast cancer (metastatic) - fulvestrant	NICE does not recommend fulvestrant instead of aromatase inhibitor drugs for postmenopausal women with locally advanced or metastatic breast cancer in various circumstances.	Fulvestrant	No
Dec-11	TA240	Colorectal cancer (metastatic) - panitumumab (terminated appraisal)	NICE is unable to recommend the use in the NHS of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer because no evidence submission was received from the manufacturer or sponsor of the technology.	Panitumumab - terminated appraisal	No
Jan-12	TA241	Leukaemia ( chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)	NICE recommends nilotinib as a possible treatment for some people with chronic myeloid leukaemia.	Dasatinib, high-dose imatinib and nilotinib	Yes
Jan-12	TA242	Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)	NICE does not recommend cetuximab ( on its own or in combination with Chemotherapy) for people with metastatic colorectal cancer that has progressed after first-line chemotherapy.	Cetuximab, bevacizumab, panitumumab	No
Jan-12	TA243	Follicular lymphoma - rituximab ( review)	NICE recommends rituximab in combination with certain chemotherapies as a possible treatment for people with stage III-IV follicular lymphoma (first-line treatment).	Rituximab	Yes
Jan-12	TA244	Chronic obstructive pulmonary disease - roflumilast	NICE recommends roflumilast for people with severe COPD only if they are taking part in a research study ( clinical trial) that is investigating using roflumilast at the same time as a bronchodilator.	Roflumilast	No
Jan-12	TA245	Venous thromboembolism - apixaban (hip and knee surgery)	NICE recommends apixaban as a possible treatment to reduce the risk of venous thromboembolism in adults.	Apixaban	Yes

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Feb-12	TA246	Venom anaphylaxis - immunotherapy pharmlagen	NICE recommends Pharmlagen as a possible treatment for some people with bee or wasp venom allergy.	Pharmlagen	No
Feb-12	TA247	Rheumatoid arthritis - tocilizumab (rapid review TA198)	This guidance updates and replaces NICE TA 198 Rheumatoid arthritis - tocilizumab.	Tocilizumab and methotrexate	Yes
Feb-12	TA248	Diabetes (type 2) - exenatide ( prolonged release)	NICE recommends prolonged-release exenatide injections, in combination with other drugs (given as tablets), as a possible treatment for some people with type 2 diabetes.	Exenatide	In progress
Mar-12	TA249	Atrial fibrillation - dabigatran etexilate	NICE recommends dabigatran etexilate as a possible treatment to prevent stroke and systemic embolism in people with atrial fibrillation.	Dabigatran etexilate	Yes
Apr-12	TA250	Breast cancer (advanced) - eribulin	NICE does NOT recommend eribulin for people with locally advanced or metastatic breast cancer that has got worse after two or more courses of chemotherapy.	Eribulin	No
Apr-12	TA251	Leukaemia ( chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib.	This guidance partially updates NICE technology appraisal guidance 70 ( published October 2003).	Nilotinib, dasatinib and imatinib	
Apr-12	TA252	Hepatitis C (genotype 1) - telaprevir	NICE recommends telaprevir with preinterferon alfa and ribavirin as a possible treatment for genotype 1 chronic hepatitis C in adults with the earlier stages of liver disease	Telaprevir, ribavirin, Peginterferon alfa	Yes
Apr-12	TA253	Hepatitis C (genotype 1) - boceprevir	NICE recommends boceprevir with peginterferon alfa and ribavirin as a possible treatment for genotype 1 chronic hepatitis C in adults with the earlier stages of liver disease (known as compensated liver disease).	boceprevir, ribavirin, peginterferon alfa	Yes
Apr-12	TA254	Multiple sclerosis (relapsing-remitting) - fingolimod	NICE has been asked to clarify whether the recommendation for the use of fingolimod extends to people with relapsing remitting multiple sclerosis who are currently receiving treatment with glatiramer acetate, and who experience an unchanged or increased relapse rate, or ongoing sever relapses compared with the previous year.	see NICE TA254	Yes
May-12	TA255	Prostate cancer - cabazitaxel	NICE does NOT recommend cabazitaxel for people with hormone-refractory metastatic prostate cancer who have had docetaxel.	Cabazitaxel	No
May-12	TA256	Atrial fibrillation (stroke prevention) - rivaroxaban	NICE recommends rivaroxaban as a possible treatment to prevent stroke and systemic embolism in some people with atrial fibrillation under certain condition.	Rivaroxaban	Yes
Jun-12	TA257	Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab ( with aromatase inhibitor)	NICE does not recommend lapatinib or trastuzumab in combination with an aromatase inhibitor for women who have been through the menopause and who have metastatic breast cancer that is hormone receptor and HER2 positive.	Lapatinib and trastuzumab	No
Jun-12	TA258	Lung cancer ( non small cell, EGFR-TK mutation positive) - erlotinib (1st line)	NICE recommends erlotinib as a possible first-line treatment for some people with locally advanced or metastatic non-small cell lung cancer.	Erlotinib	Yes
Jun-12	TA259	Prostate cancer (metastatic, castration resistant) - abiraterone (following cytotoxic therapy)	NICE recommends abiraterone as a possible treatment for some adults with metastatic prostate cancer who have already had treatment to reduce testosterone and have had docetaxel chemotherapy.	Abiraterone	Yes
Jun-12	TA260	Migraine (chronic) - botulinum toxin type A	NICE recommends botulinum toxin type A as a possible treatment for preventing headaches in some adults with chronic migraine.	Botulinum toxin type A	Yes
Jul-12	TA261	Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban	NICE recommends rivaroxaban as a possible treatment for adults with deep vein thrombosis and to help prevent a pulmonary embolism or another deep vein thrombosis.	Rivaroxaban	Yes
Jul-12	TA262	Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal)	NICE is unable to recommend the use in the NHS of adalimumab for the treatment of moderate to severe ulcerative colitis because no evidence submission was received from the manufacturer or sponsor of the technology. See full NICE TA for further details	Adalimumab- terminated appraisal	No
Aug-12	TA263	Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer	NICE does not recommend bevacizumab in combination with capecitabine as first-time treatment for metastatic breast cancer when other chemotherapy ( including taxanes or anthracyclines) is not appropriate, or taxanes or anthracyclines have been given in the past 12 months.	Bevacizumab	No
Sep-12	TA264	Stroke (acute, ischaemic) - alteplase	NICE recommends alteplase as a possible treatment for people who have had an acute ischaemic stroke	Alteplase	Yes
Oct-12	TA265	Bone metastases from solid tumours - denosumab	NICE recommends denosumab as a possible treatment for preventing complications that results from cancer spreading to the bone from solid tumours, except for prostate cancer, if the person would otherwise be prescribed a bisphosphonate. NICE does not recommend denosumab for preventing complications that result from prostate cancer spreading to the bone.	Denosumab	Yes
Nov-12	TA266	Cystic fibrosis - mannitol dry power for inhalation	NICE recommends mannitol dry powder for inhalation as a possible treatment for some adults with cystic fibrosis	Mannitol dry powder	Condition not treated at RFL
Nov-12	TA267	Chronic heart failure - ivabradine	NICE recommends ivabradine as a possible treatment for some people with chronic heart failure.	Ivabradine	Yes
Dec-12	TA268	Melanoma (stage III or IV) - ipilimumab	NICE recommends ipilimumab as a possible treatment for people with previously treated advanced (unresectable or metastatic) melanoma.	Ipilimumab	Yes

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Dec-12	TA269	Melanoma (BRAF V600 mutation positive, unresectable metastatic - vemurafenib)	NICE recommends vemurafenib as a possible treatment for unresectable or metastatic melanoma with the BRAF V 600 mutation. See full NICE TA for further details.	Vemurafenib	Yes
Dec-12	TA270	Leukaemia (acute myeloid) - decitabine (terminated appraisal)	NICE is unable to make a recommendation about the use of decitabine for acute myeloid leukaemia because no evidence submission was received from the manufacturer of the technology.	Decitabine -terminated	No
Jan-13	TA271	Diabetic macular oedema - fluocinolone acetonide intravitreal implant	NICE does not recommend fluocinolone acetonide intravitreal implants for people with chronic diabetic macular oedema when other treatments have not worked well enough. See full NICE TA for further details.	Fluocinolone acetonide	No
Jan-13	TA272	Urothelial tract carcinoma (transitional cell, advance metastatic) - vinflunine	NICE does not recommend vinflunine for people with advanced or metastatic transitional cell cancer of the urothelial tract that has been treated previously with platinum-containing cancer drugs.	Vinflunine	No
Jan-13	TA273	Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)	NICE is unable to recommend the use in the NHS of tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia because no evidence submission was received from the manufacturer of the technology.	tadalafil- terminated appraisal	No
Feb-13	TA 274	Macular oedema (diabetic) - ranibizumab	NICE recommends ranibizumab as a possible treatment for problems with sight problems due to diabetic macular oedema in some people. See full NICE TA for further details.	Ranibizumab	Yes
Feb-13	TA 275	Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) apixaban	NICE recommends apixaban as a possible treatment to prevent stroke and systemic embolism in some people with atrial fibrillation without underlying heart valve disease.	Apixaban	Yes
Mar-13	TA 276	Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin	NICE recommends colistimethate and tobramycin dry powder inhalers as possible treatment for chronic pseudomonas lung infection in some people with cystic fibrosis	Colistimethate sodium and tobramycin	Condition not treated at RFL
Mar-13	TA 277	Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care - Terminated appraisal.	NICE is unable to recommend use of methylnaltrexone for this indication because no evidence submission was received from the manufacturer	Methylnaltrexone	No
Apr-13	TA278	Asthma (severe, persistent, patients aged 6 years and over, adults- Omalizumab, (rev TA133, TA 201)	NICE recommends omalizumab as possible addition to standard asthma treatment for some people aged 6 years and over with severe persistent allergic asthma.	Omalizumab	Yes
Apr-13	TA 279	Vertebral fractures- vertebroplasty and kyphoplasty	NICE recommends vertebroplasty and kyphoplasty without stenting as possible treatment options for some people with spinal compression fractures caused by osteoporosis	Vertebroplasty and kyphoplasty	N/A - Not specific to drugs
Apr-13	TA 280	Rheumatoid arthritis abatacept (second line) - rapid review of TA 234	Abatacept in combination with methotrexate is recommended as an option for treating rheumatoid arthritis in adults whose disease has responded inadequately to 2 conventional DMARDs including methotrexate, only if it is used in accordance with the recommendations for other biological DMARDs in NICE TA 130 and in line with the PAS.	Abatacept	Yes
Apr-13	TA 281	Gout-canakinumab (terminated appraisal)	NICE is unable to recommend canakinumab for treating gouty arthritis attacks as no evidence submission received from manufacturer	canakinumab	No
Apr-13	TA 282	Idiopathic pulmonary fibrosis- pirfenidone	NICE recommends pirfenidone as an option for treating idiopathic pulmonary fibrosis if the person has FVC between 50-80% of predicted and under the terms of the PAS	Pirfenidone	Condition not treated at the RFL
May-13	TA 283	Macular oedema (retinal vein occlusion)-ranibizumab	NICE recommends ranibizumab as an option for treating visual impairment due to macular oedema following CRVO and BRVO only if laser photocoagulation has not been beneficial or when laser is not suitable because of macular haemorrhage, and in line with the PAS	Ranibizumab	Yes
May-13	TA 284	Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer	NICE does not recommend bevacizumab in combination with paclitaxel and carboplatin for first line treatment of advanced ovarian cancer (FIGO stages IIIB, IIIC and IV epithelial ovarian, fallopian tube or primary peritoneal cancer	Bevacizumab	Condition not treated at the RFL
May-13	TA 285	Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum sensitive or partially platinum-sensitive)- bevacizumab	NICE does not recommend bevacizumab in combination with gemcitabine and carboplatin for treatment of people with first recurrence of platinum-sensitive advanced ovarian cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents.	Bevacizumab	Condition not treated at the RFL
May-13	TA 286	Schizophrenia or bipolar disorder- loxapine inhalation (terminated appraisal)	NICE is unable to recommend loxapine inhalation for treatment of acute agitation and disturbed behaviour associated with schizophrenia and bipolar disorder because no evidence submission was received from the manufacturer	loxapine inhalation	No
Jun-13	TA 287	Pulmonary embolism and recurrent VTE- rivaroxaban	NICE recommends rivaroxaban as an option for treating pulmonary embolism and preventing recurrent deep venous thrombosis and pulmonary embolism in adults	Rivaroxaban	Yes
Jun-13	TA 288	Type 2 diabetes- dapagliflozin combination therapy	NICE recommends dapagliflozin in a dual therapy combination regimen with metformin as an option for treating type 2 diabetes only if used as described for DPP-4 inhibitors in NICE CG 87, and also in combination with insulin with or without other antidiabetic drugs as an option for treating type 2 diabetes. It is	Dapagliflozin	Yes
Jun-13	TA 289	Myelofibrosis (splenomegaly, symptoms) ruxolitinib	NICE does not recommend ruxolitinib for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis, or post essential thrombocythaemic myelofibrosis	Ruxolitinib	No

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Jun-13	TA 290	Overactive bladder- mirabegron	NICE recommends mirabegron as an option for treating the symptoms of overactive bladder only for people in whom antimuscarinic drugs are contra-indicated, or clinically ineffective or have unacceptable side effects.	Mirabegron	Yes
Jun-13	TA 291	Gout-(tophaceous, severe debilitating, chronic)- pegliticase	NICE does not recommend pegloticase for treating severe debilitating chronic tophaceous gout in adults who may also have erosive joint involvement and in whom xanthine oxidase inhibitors have failed to normalise serum uric acid or for whom these medicines are contra-indicated.	Pegloticase	No
Jul-13	TA 292	Bipolar disorder adolescents - (aripiprazole)	NICE recommends aripiprazole as a possible treatment (up to 12 weeks) for moderate to severe manic episodes in young people aged 13 years and older with bipolar disease	Aripiprazole	Yes
Jul-13	TA 293	Thrombocytopenic purpura - eltrombopag	NICE recommends eltrombopag as an option for treating adults with chronic immune (idiopathic) thrombocytopenic purpura in adults who have had a splenectomy and whose condition is refractory to other treatments, or as second line treatment in adults who have not had a splenectomy because surgery is contra-indicated only if their condition is refractory to standard active treatments and rescue therapies or they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies, and in line with the PAS.	Eltrombopag	Yes
Jul-13	TA 294	Macular degeneration (wet-age related) - aflibercept	NICE recommends aflibercept as an option for treating wet age-related macular degeneration only if it is used in accordance with the recommendations for ranibizumab in NICE TA 155, and in the line with the PAS.	Aflibercept	Yes
Aug-13	TA 295	Breast cancer (HER-2 negative, oestrogen receptor positive, locally advanced or metastatic)- everolimus (with an aromatase inhibitor)	NICE does NOT recommend everolimus with exemestane for treating postmenopausal women with advanced HER2 negative hormone-receptor positive breast cancer that has recurred or progressed following treatment with a non-steroidal aromatase inhibitor.	Everolimus	No
Sep-13	TA 296	Lung cancer (non-small cell, anaplastic lymphoma kinase, fusion gene, previously treated)- crizotinib	NICE does not recommend crizotinib for treating adults with previously treated anaplastic lymphoma kinase-positive advanced non-small cell lung cancer	Crizotinib	No
Oct-13	TA 297	Vitreomacular traction -Ocriplasmin	NICE recommend Ocriplasmin as an option for treating vitreomacular traction in adults only if an epi-retinal membrane is not present and they have a stage II full thickness macular hole with a diameter of 400 micrometers or less and/ or they have severe symptoms	Ocriplasmin	Yes
Nov-13	TA 298	Choroidal neovascularisation (pathological myopia) -ranibizumab	NICE recommends ranibizumab as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia, under the terms of the PAS.	Ranibizumab	In progress
Nov-13	TA 299	Leukaemia (chronic myeloid) - bosutinib	NICE does not recommend bosutinib for treating Philadelphia-chromosome-positive Chronic Myeloid Leukaemia	Bosutinib	No
Nov-13	TA 300	Hepatitis C (children and young people) - peginterferon alfa and ribavirin	NICE recommends peginterferon alfa in combination with ribavirin as an option for treating chronic hepatitis C in children and young people. Guidance updates and replaces parts of TA 75 and TA 106.	Peginterferon alfa and ribavirin	Condition not treated at the RFL
Nov-13	TA 301	Diabetic macular oedema (fluocinolone acetate intravitreal implant (rapid review of TA 271)	NICE recommends fluocinolone intravitreal implants as a possible treatment for people with chronic diabetic macular oedema that is insufficiently responsive to available therapies only if the implant is to be used in an eye with an intra-ocular pseudophakic lens and in line with the PAS.	Fluocinolone acetate intravitreal implant	Yes
Nov-13	TA 302	Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal)	NICE is unable to make a recommendation about the use of canakinumab for systemic juvenile idiopathic arthritis because no evidence submission was received from the manufacturer	canakinumab	No
Jan-14	TA 303	Multiple sclerosis(relapsing) Teriflunomide	NICE recommends teriflunomide for adults with active relapsing remitting MS under certain criteria and in line with the PAS.	Teriflunomide	Yes
Jan-14	TA 304	Arthritis of the hip - end stage	No specific drug recommendations	N/A	N/A - Not specific to drugs
Feb-14	TA 305	Macular oedema (central retinal vein occlusion)-aflibercept solution for injection	NICE recommends aflibercept as an option for treating visual impairment due to diabetic macular oedema secondary to central retinal vein occlusion in line with the PAS	Aflibercept	Yes
Feb-14	TA 306	Lymphoma (Non-Hodgkins, relapsed refractory)- pixantrone monotherapy	NICE recommends pixantrone as an option for treating adults with multiply relapsed refractory aggressive non-Hodgkins B cell lymphoma only if they have had previous rituximab and as third or fourth line treatment.	Pixantrone	Yes
Mar-14	TA 307	Colorectal cancer (metastatic) - aflibercept	NICE does not recommend aflibercept in combination with irinotecan and fluorouracil-based chemotherapy for treatment of metastatic colorectal cancer that is resistant to or has progressed after oxaliplatin-containing regimens	Aflibercept	No
Mar-14	TA 308	Vasculitis (ANCA-associated) rituximab (with glucocorticoids)	NICE recommends rituximab taken with glucocorticoids for ANCA associated vasculitis under certain criteria	Rituximab with glucocorticoids	Yes
Apr-14	TA 309	Pemetrexed maintenance for non squamous non small cell lung cancer	Pemetrexed maintenance is NOT recommended after therapy with pemetrexed and cisplatin	Pemetrexed	Yes but not for this indication
Apr-14	TA 310	Afatinib for treating epidermal growth factor receptor mutation-positive locally adv	Afatinib is recommended for treating EGFR positive advanced/ metastatic NSCLC	Afatinib	Yes

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Apr-14	TA 311	Bortezomib for induction therapy in MM before high dose chemotherapy and autologous stem cell transplant	Bortezomib is recommended as a possible treatment for this indication	Bortezomib	Yes
May-14	TA 312	Alemtuzumab for treating relapsing remitting MS	Alemtuzumab is recommended as a treatment option	Alemtuzumab	Yes
May-14	TA 313	Ustekinumab for treating active psoriatic arthritis	Ustekinumab is recommended as a possible treatment for psoriatic arthritis under certain conditions	Ustekinumab	Yes
Jun-14	TA 314	ICDs and cardiac resynchronisations for arrhythmias and heart failure	Not medicines	not medicines	NA/
Jun-14	TA 315	Canagliflozin in combination therapy for treating type 2 diabetes	Canagliflozin is recommended as an option for this indication	Canagliflozin	Yes
Jul-14	TA 316	Enzalutamide for metastatic hormone relapsed prostate cancer previously treated with docetaxel containing regimen	Enzalutamide is recommended as a possible treatment option for this indication	Enzalutamide	Yes
Jul-14	TA317	Prasugrel with PCI for treating ACS	Prasugrel is recommended as an option for this indication	Prasugrel	Yes
Jul-14	TA318	Lubiprostone for treating chronic idiopathic constipation	Lubiprostone is recommended as an option under certain circumstances	Lubiprostone	In progress
Jul-14	TA 319	Ipilimumab for previously untreated advanced melanoma	Ipilimumab is recommended as a possible treatment for this indication	Ipilimumab	Yes
Aug-14	TA320	DMF for treating relapsing remitting MS	DMF is recommended as an option for this indication	DMF	Yes
Oct-14	TA 321	Dabrafenib for treating unresectable or metastatic BRAF V 600 mutation positive melanoma	Dabrafenib is recommended as a possible treatment option for this indication	Dabrafenib	Yes
Oct-14	TA 322	Lenalidomide for treating MDS associated with deletion 5q abnormality	Lenalidomide is recommended as an option for this indication	Lenalidomide	Yes
Nov-14	TA 323	Erythropoiesis stimulating agents (erythropoetin and darbepoetin for treating anaemia in people with cancer having chemotherapy)	Erythropoetin and darbepoetin are recommended for this indication	Erythropoetin and darbepoetin	Yes
Nov-14	TA 324	Dual chamber pacemakers	Not medicines	Not medicines	NA
Nov-14	TA 325	Nalmefene for reducing alcohol consumption in people with alcohol dependency	Nalmefene is recommended as an option for this indication under certain conditions	nalmefene	In progress
Nov-14	TA 326	Imatinib for adjuvant treatment of GIST	Imatinib is recommended as a treatment under certain conditions	Imatinib	Yes but condition not treated at RFL
Dec-14	TA 327	Dabigatran for treatment and secondary prevention of DVT and / or PE	Dabigatran is recommended as an option for this indication	Dabigatran	Yes
Dec-14	TA 328	Idelalisib for treating follicular lymphoma that is refractory to two prior treatments TERMINATED APPRAISAL	NICE is unable to make a recommendation on Idelalisib for this indication	Idelalisib -TERMINATED appraisal	Not for this indication
Feb-15	TA329	Infliximab, golimumab and adalimumab for treating moderate to severely active UC after failure of conventional therapy	Infliximab, golimumab and adalimumab are recommended as options for this indication in adults. Infliximab is also recommended as an option in children and adolescents.	Infliximab, golimumab and adalimumab	Yes
Feb-15	TA 330	Sofosbuvir for treating chronic hepatitis C	Sofosbuvir is recommended as a possible treatment under certain conditions	Sofosbuvir	Yes
Feb-15	TA 331	Simeprevir with pegylated interferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C	Simeprevir is recommended as a possible treatment for adults with genotypes 1 and 4 hep C	Simeprevir	Yes
Feb-15	TA332	Sipuleucel-T for treating asymptomatic or minimally symptomatic hormone relapsed prostate cancer	Sipuleucel-T is NOT recommended for this indication. APPRAISAL WITHDRAWN	Sipuleucel T	No
Feb-15	TA333	Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment	Axitinib is recommended as a possible treatment for this indication	Axitinib	Yes
Feb-15	TA334	Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)	NICE is unable to make a recommendation on regorafenib for this indication	Regorafenib	No
Mar-15	TA335	Rivaroxaban for preventing adverse outcomes after ACS	Rivaroxaban is recommended as a possible treatment for this indication	Rivaroxaban	Yes
Mar-15	TA336	Empagliflozin in combination therapy for treating type 2 diabetes	Empagliflozin is recommended for this indication under certain criteria	Empagliflozin	Yes
Mar-15	TA337	Rifaximin for preventing episodes of overt hepatic encephalopathy	Rifaximin is recommended for this indication	Rifaximin	Yes
Mar-15	TA338	Pomalidomide for relapsed and refractory MM previously treated with lenalidomide and bortezomib	Pomalidomide is NOT recommended for this indication	Pomalidomide	No
Jun-15	TA339	Omalizumab for previously treated chronic spontaneous urticaria	Omalizumab is recommended as a possible treatment for this indication	Omalizumab	Yes
Jun-15	TA340	Ustekinumab for treating active psoriatic arthritis	Ustekinumab is recommended as a possible treatment under certain criteria	Ustekinumab	Yes
Jun-15	TA341	Apixaban for treatment and secondary prevention of DVT and / or PE	Apixaban is recommended as an option for this indication	Apixaban	Yes
Jun-15	TA342	Vedolizumab for treating moderate to severely active	Vedolizumab is recommended as a possible treatment for this indication	Vedolizumab	Yes
Jun-15	TA343	Obinutuzumab with chlorambucil for untreated CLL	Obinutuzumab is recommended as a possible treatment for this indication under certain conditions	Obinutuzumab	
Jun-15	TA344	Ofatumumab with chlorambucil or bendamustine for untreated CLL	Ofatumumab is recommended for this indication	Ofatumumab	Yes
Jul-15	TA345	Nalogexol for treating opioid induced constipation	Nalogexol is recommended as an option for this indication	Naogexol	In progress
Jul-15	TA346	Aflibercept for treating diabetic macular oedema	Aflibercept is recommended as an option	Aflibercept	Yes
Jul-15	TA347	Nintedanib for previously treated locally advanced metastatic or locally recurrent non-small cell lung cancer	Nintedanib is recommended as an option	Nintedanib	Yes
Jul-15	TA348	Everolimus for preventing organ rejection in liver transplantation	Everolimus is NOT recommended for this indication	Everolimus	No
Jul-15	TA349	Dexamethasone intravitreal implant for treating diabetic macular oedema	Dexamethasone is recommended for this indication under certain criteria	Dexamethasone intravitreal	Yes
Jul-15	TA 350	Secukinumab for treating moderate to severe plaque psoriasis	Secukinumab is recommended as a possible option under certain criteria	Secukinumab	Yes
Jul-15	TA 351	Cangrelor for people undergoing PCI or awaiting surgery and requiring interruption of antiplatelet therapy TERMINATED APPRAISAL	Cangrelor	Cangrelor	No (terminated appraisal- drug not on Formulary)
Aug-15	TA352	Vedolizumab for moderate to severe active Crohn's disease after prior therapy	Vedolizumab is recommended as a possible treatment for this indication when TNF alfa is not effective or not tolerated	Vedolizumab	Yes
Aug-15	TA353	Bevacizumab for relapsed platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (TERMINATED APPRAISAL)	NICE is unable to make a recommendation on this	Bevacizumab	No (terminated appraisal- drug not on Formulary)

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Aug-15	TA354	Edoxaban for treating and preventing DVT and PE	Edoxaban is recommended as an option for this indication	Edoxaban	In progress
Sep-15	TA355	Edoxaban for preventing stroke and systemic embolism in people with non valvular AF	Edoxaban is recommended as an option for this indication	Edoxaban	Yes
Sep-15	TA356	Ruxolitinib for treating polycythaemia vera	NICE is unable to make a recommendation on this	Ruxolitinib	No (terminated appraisal- drug not on Formulary for this indication)
Oct-15	TA357	Pembrolizumab for treating advanced melanoma after progression on ipilimumab	Pembrolizumab is recommended for this indication	Pembrolizumab	Yes
Oct-15	TA358	Tolvaptan for treating autosomal dominant polycystic kidney disease	Tolvaptan is recommended for this indication	Tolvaptan	Yes
Oct-15	TA359	Idelalisib for treating chronic lymphocytic leukaemia	Idelalisib is recommended for this indication under certain conditions	Idelalisib	In progress
Oct-15	TA360	Paclitaxel albumin bound nanoparticles with gemcitabine for previously untreated metastatic pancreatic cancer	Paclitaxel albumin bound nanoparticles are not recommended for adults with previous ly untreated metastatic adenocarcinoma of the pancreas	Albumin bound paclitaxel	No (drug not recommended)
Oct-15	TA361	Simeprevir in combination with sofosbuvir for treating chronic genotype 1 or 4 hepatitis C infection (TERMINATED APPRAISAL)	NICE is unable to make a recommendation on this combination for this indication	Simeprevir	Yes (but not in this combination)
Oct-15	TA362	Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non small cell lung cancer (TERMINATED APPRAISAL)	NICE is unable to make a recommendation on this	Paclitaxel as albumin bound nanoparticles	No (terminated appraisal - drug not on Formulary)
Nov-15	TA363	Ledipasvir -sofosbuvir for treating chronic hepatitis C	Ledipasvir is recommended as an option for this indication	Ledipasvir	Yes
Nov-15	TA364	Daclatasvir for treating chronic hepatitis C	Daclatasvir is recommended as a possible treatment under certain conditions	Daclatasvir	Yes
Nov-15	TA365	Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C	Ombitasvir-paritaprevir-ritonavir - dasabuvir are recommended as options for this indication under certain criteria	Ombitasvir-paritaprevir-ritonavir, dasabuvir	Yes
Nov-15	TA366	Pembrolizumab for advanced melanoma not previously treated with ipilimumab	Pembrolizumab is recommended for this indication	Pembrolizumab	Yes
Nov-15	TA367	Vortioxetine for treating major depressive episodes	Vortioxetine is recommended as a possible treatment under certain conditions	Vortioxetine	In progress
Nov-15	TA368	Apremilast for treating moderate to severe plaque psoriasis	Apremilast is NOT recommended for this indication	Apremilast	No (drug is not recommended and not on Formulary)
Dec-15	TA369	Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears	Ciclosporin eye drops (Ikervis)	Ciclosporin	Yes
Dec-15	TA370	Bortezomib for previously untreated mantle cell lymphoma	Bortezomib is recommended as an option for this indication under certain conditions	Bortezomib	In progress
Dec-15	TA371	Trastuzumab emtansine for HER2 positive locally advanced or metastatic breast cancer after trastuzumab and taxane	Trastuzumab emtansine is NOT recommended for this indication	Trastuzumab emtansine	No (drug is not recommended and not on RFL Formulary)
Dec-15	TA372	Apremilast for treating active psoriatic arthritis	Apremilast is NOT recommended for this indication	Apremilast	No (drug is not recommended and is not on Formulary)
Dec-15	TA 373	Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis	These drugs are recommended for this indication under certain criteria	Abatacept, etanercept, adalimumab and tocilizumab	This indication is not treated at the RFL
Dec-15	TA374	Erlotinib and gefitinib for treating non small cell lung cancer that has progressed after prior chemotherapy	Erlotinib is recommended for this indication under certain criteria and NOT recommended for this indication after non- targeted chemotherapy in tumours that are EGFR-TK mutation negative. Gefitinib is NOT recommended for this indication after non- targeted chemotherapy in people with tumours that are EGFR-TK positive.	Erlotinib and gefitinib	Yes (for approved indication only)
Jan-16	TA 375	Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab	These medicines are recommended as options for RA as specified in NICE TA criteria	Adalimumab, etanercept, infliximab, certolizumab, golimumab and tocilizumab	Yes
Jan-16	TA 376	Radium 223 for treating hormone-relapsed prostate cancer with bone metastases	Radium 223 is recommended for this indication as specified in the NICE TA criteria	Radium 223	Yes
Jan-16	TA 377	Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	Enzalutamide is recommended as a possible treatment option for this indication under specific criteria in the NICE TA	Enzalutamide	Yes
Jan-16	TA 378	Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy	Ramucirumab alone or with paclitaxel is NOT recommended for this indication	Ramucirumab	No (condition is not treated at the RFL and drug is NOT on RFL Formulary)
Jan-16	TA 379	Nintedanib for treating idiopathic pulmonary fibrosis	Nintedanib is recommended as an option for this indication under specific criteria in the NICE TA	Nintedanib	In progress
Jan-16	TA 380	Panobinostat for treating multiple myeloma after at least two previous treatments	Panobinostat is recommended as an option for this indication under certain criteria	Panobinostat	Yes
Jan-16	TA 381	Olaparib for maintenance treatment of relapsed platinum-sensitive BRCA mutation-positive ovarian, fallopian and peritoneal cancer after response to second line or subsequent platinum-based chemotherapy	Olaparib is recommended for this indication under certain criteria	Olaparib	No and N/A - conditions not treated at the RFL
Jan-16	TA 382	Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)	NICE is unable to make a recommendation on this indication.	Eltrombopag	No - (drug is not recommended and is not on RFL Formulary for this indication)
Feb-16	TA 383	TNF-alfa inhibitors for ankylosing spondylitis and non-radiographic spondyloarthritis	Adalimumab, certolizumab, etanercept, golimumab and infliximab are recommended as options for these indications under certain criteria	TNF alfa inhibitors	Yes
Feb-16	TA 384	Nivolumab for treating advanced (unresectable or metastatic melanoma)	Nivolumab as monotherapy is recommended as an option for this indication	Nivolumab	Yes
Feb-16	TA 385	Ezetimibe for treating primary heterozygous familial and non-familial hypercholesterolaemia	Ezetimibe is recommended as an option under certain criteria	Ezetimibe	Yes

**Royal Free London NHS Foundation Trust**  
**NICE Technology Appraisals and Drug Formulary Indications 2000 - to date**

Date	TA ref	TA Title	NICE Summary / recommendation	comments	On RFL Formulary YES / NO
Mar-16	TA 386	Ruxolitinib for treating disease-related splenomegaly in adults with myelofibrosis	Ruxolitinib is recommended as an option for this indication under certain criteria	Ruxolitinib	Yes
Apr-16	TA 387	Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	Abiraterone is recommended as an option for this indication	Abiraterone	Yes
Apr-16	TA 388	Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction	Sacubitril valsartan is recommended for this indication under certain criteria	Sacubitril valsartan	In progress
Apr-16	TA 389	Topotecan, pegylated liposomal doxorubicin, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer		Topotecan, pegylated liposomal doxorubicin, paclitaxel, trabectedin and gemcitabine	N/A (condition is not treated at the RFL)
May-16	TA 390	Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes	These medicines as monotherapies are recommended as options for this indication under certain criteria	Canagliflozin, dapagliflozin and empagliflozin	In progress
May-16	TA 391	Cabazitaxel for hormone-relapsed metastatic prostatic cancer treated with docetaxel	Cabazitaxel is recommended as an option for this indication	Cabazitaxel	Yes
Jun-16	TA 392	Adalimumab for treating moderate to severe hidradenitis suppurativa	Adalimumab is recommended as an option for this indication under certain criteria	Adalimumab	Yes
Jun-16	TA 393	Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia	Alirocumab is recommended as an option under certain criteria	Alirocumab	In progress
Jun-16	TA 394	Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia	Evolocumab is recommended as an option under certain criteria	Evolocumab	In progress
Jun-16	TA 395	Ceritinib for previously treated anaplastic lymphoma kinase positive non-small cell lung cancer	Ceritinib is recommended as an option for this indication	Ceritinib	In progress
Jun-16	TA 396	Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma	Trametinib with dabrafenib is recommended as an option for this indication in adults with a BRAF V600 mutation	Trametinib with dabrafenib	Yes
Jun-16	TA 397	Belimumab for treating active autoantibody-positive SLE	Belimumab is recommended as an option for this indication	Belimumab	Yes
Jul-16	TA 398	Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508 del mutation	Lumacaftor-ivacaftor is NOT recommended for this indication	Lumacaftor-ivacaftor	No (condition is not treated at the RFL and drug is not on RFL Formulary)
Jul-16	TA 399	Azacitidine for treating acute myeloid leukaemia with more than 30% marrow blasts	Azacitidine is NOT recommended for this indication	Azacitidine	No -drug is not recommended and is not on RFL formulary for this indication)
Jul-16	TA 400	Nivolumab in combination with ipilimumab for treating advanced melanoma	Nivolumab with ipilimumab are recommended as options for this indication	Nivolumab with ipilimumab	Yes
Aug-16	TA 401	Bosutinib for previously treated CML	Bosutinib is recommended as an option for this indication under certain criteria	Bosutinib	In progress
Aug-16	TA 402	Pemetrexed maintenance treatment for non-squamous, non-small cell lung cancer after pemetrexed and cisplatin	Pemetrexed maintenance is recommended as an option under certain criteria	Pemetrexed	In progress
Aug-16	TA 403	Ramucirumab for previously treated locally advanced or metastatic non-small cell lung cancer	Ramucirumab is NOT recommended for this indication	Ramucirumab	No (drug is not recommended and is not on RFL Formulary)